| Literature DB >> 35479515 |
Cristina Vercelli1, Graziana Gambino1, Michela Amadori2, Giovanni Re1.
Abstract
Antimicrobial resistance (AMR) is defined by the entire scientific community as the major threat for human health and it is responsible for an increase in morbidity and mortality rates. The reasons behind this phenomenon are complex and the solution is achievable only considering the One Health approach, that encompasses the integration and implementation of human health, veterinary medicine and environmental status. Authors aimed to write this review to summarize to readers the three milestones of One-Health, underlying the most important topics in which veterinary medicine is mostly involved. Therefore, a short introduction about the history of AMR in veterinary medicine is provided, then more detailed aspects about the impact of AMR related to pets, food producing animals, wild animals and environment are discussed. Finally, some critical aspects about current and future issues are considered.Entities:
Keywords: Antimicrobial resistance; Companion animals; Exotic animals; Food producing animals; One Health approach
Year: 2022 PMID: 35479515 PMCID: PMC9036142 DOI: 10.1016/j.vas.2022.100249
Source DB: PubMed Journal: Vet Anim Sci ISSN: 2451-943X
Fig. 1The figure represents the workflow to select literature for the present review.
The table compares the main antibiotic families categorized by Antimicrobial Advice Ad Hoc Expert Group (AMEG) and World Health Organization (WHO). Following the AMEG classification, the categories are A= avoid, B= restrict, C=caution and D= prudence. The parallel Who ranking from the highest to the lowest degree is critical important antibiotics highest priority, critically important antibiotics high priority, highly important antimicrobials, important antimicrobials.
| AMEG | WHO | |
| Aminoglycosides | C | High Priority |
| Cephalosporins 3°-4° | B | Highest Priority |
| Macrolides | C | Highest Priority |
| Penicillins | D | Highly important |
| Polymyxin | B | Highest Priority |
| Quinolones | B | Highest Priority |
| Tetracyclines | D | High Priority |
| Amphenicols | C | Highly important |
| Aminopenicillins | C | High Priority |
| Rifamycins | C | High Priority |
| Cephalosporins 1°-2° | C | Highly important |
| Lincosamides | C | Highly important |
| Pleuromotilins | C | Important |
| Streptogramins | A | Highly important |
| Sulfonamides | D | Highly important |
| Glycopeptides | A | Highest Priority |
| Oxazolidines | A | High Priority |
Fig. 2The figure represents the five key points of the educational plans for professionals and consumers designed by World Health Organization (WHO) global action plan (adapted by Collignon and McEwen, 2019)